Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus SEREVENT.
ISOETHARINE HYDROCHLORIDE S/F vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist